Passage Bio Inc
PASG
NASDAQ
Biotechnology
$4.59
USD
+0.02 (+0.33%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $14.80M
Volume 2.2K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-36.11M
TTM
+36.5%
YoY
Operating Cash Flow
$-33.50M
TTM
+7.1%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 4.5 | 4.3 | 4.9 | 4.8 | 6.9 |
Other Operating Expenses | 0.0 | 0.0 | 3.5 | 0.0 | -1.9 |
Total Operating Expenses | 10.3 | 8.7 | 13.8 | 8.9 | 8.3 |
Operating Income | -10.3 | -8.7 | -13.8 | -8.9 | -8.3 |
EBITDA | -10.2 | -8.5 | -10.2 | -8.8 | -10.2 |
Other Income / Expense | 0.9 | 0.9 | 0.9 | 1.3 | 0.5 |
Total Other Income / Expense | 0.9 | 0.9 | 0.9 | 1.3 | 0.5 |
Income Before Income Taxes | -9.4 | -7.7 | -13.0 | -7.6 | -7.8 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -9.4 | -7.7 | -13.0 | -7.6 | -7.8 |
Consolidated Net Income / Loss | -9.4 | -7.7 | -13.0 | -7.6 | -7.8 |
Net Income Attributable to Common Shareholders | -9.4 | -7.7 | -13.0 | -7.6 | -7.8 |
Basic EPS | -$2.96 | -$2.44 | -$4.08 | -$2.36 | -$2.44 |
Diluted EPS | -$2.96 | -$2.44 | -$4.08 | -$2.36 | -$2.44 |
Basic Shares Outstanding | 3.2M | 3.2M | 3.2M | 3.2M | 3.2M |
Diluted Shares Outstanding | 3.2M | 3.2M | 3.2M | 3.2M | 3.2M |